Drug Profile
Iontophoretic warts therapy - NB Therapeutics
Latest Information Update: 12 Aug 2015
Price :
$50
*
At a glance
- Originator NB Therapeutics
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Warts
Most Recent Events
- 12 Jan 2011 Iontophoretic warts therapy is available for licensing in USA, Canada, European Union, Australia, Japan as of 12 Jan 2011. http://www.nitricbio.com
- 12 Jan 2011 Phase-II clinical trials in Warts in USA (Transdermal)